These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 37316442)

  • 1. [Chinese Expert Consensus on Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2023 Edition)].
    Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Committee
    Zhongguo Fei Ai Za Zhi; 2023 May; 26(5):325-337. PubMed ID: 37316442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.
    Hu M; Zhong C; Wang J; Chen J; Zhou T
    Front Immunol; 2024; 15():1399975. PubMed ID: 38774882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer.
    Geng D; Guo Q; Huang S; Zhang H; Guo S; Li X
    Clin Transl Oncol; 2022 Feb; 24(2):379-387. PubMed ID: 34453698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC.
    Ou SI; Hong JL; Christopoulos P; Lin HM; Vincent S; Churchill EN; Soeda J; Kazdal D; Stenzinger A; Thomas M
    J Thorac Oncol; 2023 Jun; 18(6):744-754. PubMed ID: 36738930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.
    Yang G; Li J; Xu H; Yang Y; Yang L; Xu F; Xia B; Zhu VW; Nagasaka M; Yang Y; Li Y; Qiu W; Ying J; Ou SI; Wang Y
    Lung Cancer; 2020 Jul; 145():186-194. PubMed ID: 32336530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies.
    Bai Q; Wang J; Zhou X
    Cancer Treat Rev; 2023 Nov; 120():102605. PubMed ID: 37703723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.
    Yang GJ; Li J; Xu HY; Sun Y; Liu L; Li HS; Yang L; Zhang Y; Li GH; Wang Y
    Lung Cancer; 2021 Feb; 152():39-48. PubMed ID: 33341538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the Diagnosis and Treatment of Advanced Non-Small-Cell Lung Cancer With EGFR Exon 20 Insertion Mutation.
    Liu J; Xiang Y; Fang T; Zeng L; Sun A; Lin Y; Lu K
    Clin Lung Cancer; 2024 Mar; 25(2):100-108. PubMed ID: 38172024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expert consensus on clinical practice of EGFR exon20 insertion detection in non-small cell lung cancer in China (2024 edition)].
    ;
    Zhonghua Zhong Liu Za Zhi; 2024 Mar; 46(3):179-188. PubMed ID: 38494765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real-world genomic datasets.
    Viteri S; Minchom A; Bazhenova L; Ou SI; Bauml JM; Shell SA; Schaffer M; Gu J; Rose JB; Curtin JC; Mahadevia P; Girard N
    Mol Oncol; 2023 Feb; 17(2):230-237. PubMed ID: 36269676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions.
    Chen K; Pan G; Cheng G; Zhang F; Xu Y; Huang Z; Fan Y
    Thorac Cancer; 2021 Jan; 12(2):218-226. PubMed ID: 33210451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Progress in Detection of EGFR Exon 20 Insertion Mutation and Targeted Therapies 
in Non-small Cell Lung Cancer].
    Wang Y; Chu T
    Zhongguo Fei Ai Za Zhi; 2023 Feb; 26(2):135-147. PubMed ID: 36872052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
    Yasuda H; Ichihara E; Sakakibara-Konishi J; Zenke Y; Takeuchi S; Morise M; Hotta K; Sato M; Matsumoto S; Tanimoto A; Matsuzawa R; Kiura K; Takashima Y; Yano S; Koyama J; Fukushima T; Hamamoto J; Terai H; Ikemura S; Takemura R; Goto K; Soejima K
    Lung Cancer; 2021 Dec; 162():140-146. PubMed ID: 34808485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 Trial.
    Duan J; Wu L; Yang K; Zhao J; Zhao Y; Dai X; Li M; Xie Y; Yao Y; Zhao M; Zhou C; Ren X; Liu Z; Pan Y; Li Y; Liu B; Cheng Y; Miao L; Yu Q; Zhang Z; Liu X; Cui J; Zhang Y; Zhang L; Li X; Li X; Shen B; Chen B; Zeng S; Li B; Hu Y; Li L; Wu R; Song Q; Wang J
    J Thorac Oncol; 2024 Feb; 19(2):314-324. PubMed ID: 37776953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.
    Floc'h N; Martin MJ; Riess JW; Orme JP; Staniszewska AD; Ménard L; Cuomo ME; O'Neill DJ; Ward RA; Finlay MRV; McKerrecher D; Cheng M; Vang DP; Burich RA; Keck JG; Gandara DR; Mack PC; Cross DAE
    Mol Cancer Ther; 2018 May; 17(5):885-896. PubMed ID: 29483211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Clinical Outcomes for Patients with
    Li K; Bosdet I; Yip S; Ho C; Laskin J; Melosky B; Wang Y; Sun S
    Curr Oncol; 2023 Jul; 30(8):7099-7111. PubMed ID: 37622996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Validation of Companion Diagnostics for the Selection of Patients with Non-Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab.
    Jatkoe T; Wang S; Odegaard JI; Velasco Roth AM; Osgood D; Martinez G; Lucas P; Curtin JC; Karkera J
    J Mol Diagn; 2022 Nov; 24(11):1181-1188. PubMed ID: 35963523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations.
    Chen H; Hu S; Patterson AV; Smaill JB; Ding K; Lu X
    J Med Chem; 2023 Sep; 66(17):11656-11671. PubMed ID: 37669428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations.
    Wu JY; Yu CJ; Shih JY
    Clin Lung Cancer; 2019 Nov; 20(6):e620-e630. PubMed ID: 31327643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China.
    Yang G; Yang Y; Liu R; Li W; Xu H; Hao X; Li J; Zhang S; Xu F; Lei S; Wang Y
    Cancer Med; 2023 Jan; 12(1):335-344. PubMed ID: 35608132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.